Additional work utilizing the CRISPR/Cas9 genome editing in vitro revealed that among hematopoietic cancer cell lines, those derived from AML patients were the most SMARCA5 dependent [21]. This evidence concerns the gene SMARCA5 and acute myeloid leukemia.